CRISPR Therapeutics (CRSP) Misses Q4 EPS by 20c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q4 EPS of ($1.37), $0.20 worse than the analyst estimate of ($1.17). Revenue for the quarter came in at $860 thousand versus the consensus estimate of $5.66 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Bending Spoons valuation up to $19 Billion in U.S. IPO - Reuters
• OpenAI launches open-source security program with Trail of Bits